Q-omics provides the consensus-scored PCDHGB7 profile across patient tissues and cancer cell-line models. PCDHGB7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCDHGB7 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, PCDHGB7 RNA expression shows 17,896 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where PCDHGB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGB7 survival associations across molecular data types. PCDHGB7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGB7 RNA expression–survival associations across cancer types. High PCDHGB7 expression shows unfavorable associations in UVM, READ and LUSC, but favorable associations in KIRC, PAAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for PCDHGB7 RNA expression.
This table summarizes PCDHGB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDHGB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGB7 shows lower tumor expression in BLCA, KICH, UCEC, LUAD and HNSC and higher tumor expression in KIRC. The BLCA box plot shows higher PCDHGB7 RNA expression in normal versus tumor tissue (log2 FC = −1.500, t-test p < 0.001).
This table shows molecular features associated with PCDHGB7 in patient tissues and cancer cell lines. In patient samples, PCDHGB7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
